In the present study, the underlying oncogenic mechanism of STK32C was explored in colorectal cancers, based on previous evidence that STK32C is highly expressed in bladder cancer24 and also is a molecular target for doxorubicin resistance in breast cancer33. The gene discussed is STK32C; the disease is colorectal cancer.